Analysis of the spectrum of genetic alterations in EFR3A across all human cancers (cBioportal cancer genomics datasets, n = 10,967 samples in total) revealed that PDAC exhibits the highest EFR3A amplification (almost 12% of cases) among all neoplasms. This evidence concerns the gene EFR3A and neoplasm.